Webinar

The GLP-1 Advantage: Ensuring Efficacy and Functionality With Advanced Drug Delivery Solutions

  • How GLP-1 peptide sensitivity to aggregation, oxidation, and hydrophobic interaction drives precise material selection requirements across compound purity, coating, and combiseal design for pen injector and prefilled syringe formats
  • What upgrading from a standard plunger and lacquered combiseal to a NeoFlex™ plunger and DuraCoat™ combiseal delivers in practice — including up to 100x reductions in airborne particle counts and stable injection times through consistent glide force
  • How EU GMP Annex 1 contamination control strategy requirements apply to GLP-1 fill-finish operations — from intrinsic particulate control through coated components to aseptic transfer via RTP bag configurations

Status Published
Format Webinar
Language English
Access Registration Required
Resource Overview

About this Webinar

GLP-1 receptor agonist therapies represent one of the highest-growth segments in injectable drug delivery — but their chemically sensitive peptide structures, self-administration requirements, and mass-market scale introduce packaging challenges that demand precise material selection, optimized component design, and rigorous contamination control across the full development and commercial lifecycle.

This on-demand webinar provides a structured technical framework for pharmaceutical packaging teams developing GLP-1 therapies in pen injector pharmaceutical cartridge and prefilled syringe formats — from molecular sensitivity and material requirements through to Annex 1 compliance strategies for fill-finish operations.

KEY TOPICS COVERED

GLP-1 peptide sensitivity and material requirements

GLP-1 peptides are susceptible to aggregation from extractables exposure, oxidation from reactive leachables, and hydrophobic destabilization — making compound purity, chemical compatibility, physical sealing performance, and biocompatibility compliance non-negotiable requirements for every component in contact with the drug. FM457's ultra-low extractables BIMS formulation is presented as the primary compound solution, with NeoFlex™ fluoropolymer spray coating providing an additional inert barrier for the most sensitive formulations..

DuraCoat™ combiseals and particulate performance

DuraCoat™ combiseals are evaluated for their role in eliminating lacquered aluminum particulate generation in GLP-1 fill-finish operations — with supporting customer data confirming 10–100x reductions in airborne particle counts versus standard lacquered combiseals. For GLP-1 manufacturers operating at mass-market scale, particulate control at the combiseal level is a direct input to product quality, reject rates, and Annex 1 compliance.

Optimized plunger design: Advanced vs FirstLine® V9520

A detailed case study contrasts a standard Advanced-tier 3mL pharmaceutical cartridge plunger against the optimized FirstLine® V9520 design — demonstrating how undercut trim edge geometry, asymmetric orientability, cone dead-volume reduction, and stricter FirstLine® bioburden (0.2 CFU/product) and endotoxin (0.1 EU/product) specifications translate into stable injection times, lower reject rates, and improved container closure integrity.

EU GMP Annex 1 compliance for GLP-1 fill-finish operations

The session concludes with Annex 1 compliance strategies for GLP-1 packaging, covering intrinsic and extrinsic particulate origins, the role of coatings in minimizing silicone-derived particles, validated washing and sterilization processes, and RTP bag configurations for Annex 1-compliant aseptic transfer — giving quality and regulatory teams a practical framework for building and defending a contamination control strategy at the component level.

WHO THIS WEBINAR IS FOR

This session is designed for pharmaceutical packaging engineers, formulation scientists, quality assurance and regulatory affairs professionals, and procurement leads developing or qualifying GLP-1 receptor agonist therapies in pen injector cartridge and prefilled syringe formats.
Watch the Webinar

Watch the Webinar On-Demand

Start the on-demand session instantly after quick registration.

Watch the Webinar
Quick access in under 30 seconds.
Expert Spotlight

Meet the Expert

Mieke Nivelle, PhD

Mieke Nivelle, PhD

Manager Surface Development Healthcare · Datwyler

Since 2022, Mieke started as Manager Surface Development Healthcare for Datwyler, acting as a subject matter expert for packaging materials, washing treatments and application testing of pharmaceutical closures. As a researcher, she is very eager to expand her knowledge about current materials and processes in view of the development of new products, treatments and test methods.

After her Master in Bioscience Engineering at the University of Leuven, Belgium, Mieke Nivelle acquired a Ph.D. in Starch Polymer Functionality and Water Mobility for Bread Making. 

TECHNICAL RESOURCES

Stay informed on Datwyler Healthcare technical resources

Subscribe to receive updates on webinars, white papers, technical articles, brochures, and expert insights from our team.